Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008

Journal of Viral Hepatitis

Volumn 17, Issue 9, 2010, Pages 650-660

  Michel, Laurent ^a,b,c   Villes, V ^d,e   Dabis, F ^f   Spire, B ^d,e   Winnock, M ^f   Loko, M A ^f   Poizot Martin, I ^g   Valantin, M A ^f,h   Bonnard, P ⁱ   Salmon Ceron D ^b,j   Carrieri, M P ^d,e  

^a Universite Paris Sud   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Hôpitaux Universitaires Henri Mondor   (France)

^d AIX MARSEILLE UNIV   (France)

^e OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^f INSERM   (France)

^g HÔPITAL SAINTE MARGUERITE   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ HÔPITAL TENON   (France)

^j Université Pierre et Marie Curie ^*  (France)

more..

Author keywords

ART; depression; fatigue; hepatitis C; quality of life

Indexed keywords

ATAZANAVIR; COCAINE; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEPRESSION; FATIGUE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIXED INFECTION; PRIORITY JOURNAL; QUESTIONNAIRE; SCREENING; SELF REPORT; SEX DIFFERENCE; SOCIAL BEHAVIOR; UNEMPLOYMENT;

EID: 77955375466     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01223.x     Document Type: Article

References (63)

1. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998 27 (1 209 212.
2. Poynard T, Cacoub P, Ratziu V et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 2002 9 (4 295 303.
3. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy.The Consensus Interferon Study Group. Hepatology 1999 29 (1 264 270.
4. APA. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th edn. Washington, DC : APA, 1994.
5. Barroso J, Lynn MR. Psychometric properties of the HIV-Related Fatigue Scale. J Assoc Nurses AIDS Care 2002 13 (1 66 75.
6. Henderson M, Safa F, Easterbrook P, Hotopf M. Fatigue among HIV-infected patients in the era of highly active antiretroviral therapy. HIV Med 2005 6 (5 347 352.
7. Breitbart W, McDonald MV, Rosenfeld B, Monkman ND, Passik S. Fatigue in ambulatory AIDS patients. J Pain Symptom Manage 1998 15 (3 159 167.
8. Voss JG. Predictors and Correlates of Fatigue in HIV/AIDS. J Pain Symptom Manage 2005 29 (2 173 184.
9. Ferrando S, Evans S, Goggin K, Sewell M, Fishman B, Rabkin J. Fatigue in HIV illness: relationship to depression, physical limitations, and disability. Psychosom Med 1998 60 (6 759 764.
10. Gutteling JJ, de Man RA, van der Plas SM, Schalm SW, Busschbach JJ, Darlington AS. Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther 2006 11 : 1629 1635.
11. Kallman J, O'Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007 52 (10 2531 2539. (Pubitemid 47373904)
12. Marcellin F, Preau M, Dellamonica P et al. Adding HCV treatment to HIV treatment in HIV-HCV coinfected patients: the impact on the different dimensions of fatigue and self-reported side effects. J Pain Symptom Manage 2007 34 (4 413 421.
13. Braitstein P, Montessori V, Chan K et al. Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: outcomes from a population-based cohort. AIDS Care 2005 17 (4 505 515.
14. Marcellin F, Preau M, Ravaux I, Dellamonica P, Spire B, Carrieri MP. Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research. HIV Clin Trials 2007 8 (5 320 327.
15. Thein H, Maruff P, Krahn M et al. Cognitive function, mood and health-related quality of life in hepatitis C virus (HCV)-monoinfected and HIV/HCV-coinfected individuals commencing HCV treatment. HIV Med 2007 8 (3 192 202.
16. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994 18 (Suppl. 1 S79 S83.
17. Fuhrer R, Rouillon F. La version française de l'échelle CES-D. Description and translation of the autoevaluation scale (in French). Psychiatrie et Psychobiologie 1989 4 : 163 166.
18. Justice AC, Holmes W, Gifford AL et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol 2001 54 (Suppl. 1 S77 S90.
19. Gama H, Correia S, Lunet N. Questionnaire design and the recall of pharmacological treatments: a systematic review. Pharmacoepidemiol Drug Saf 2009 18 (3 175 187.
20. Cotterchio M, Kreiger N, Darlington G, Steingart A. Comparison of self-reported and physician-reported antidepressant medication use. Ann Epidemiol 1999 9 (5 283 289.
21. Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003 29 (12 1705 1713.
22. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001 357 (9262 1069 1075.
23. Nelder JA, Wedderburn RWM. Generalized linear models. J Roy Stat Soc 1972 135 : 370 384.
24. Katz MH, Douglas JM Jr., Bolan GA et al. Depression and use of mental health services among HIV-infected men. AIDS Care 1996 8 (4 433 442.
25. Fairfield KM, Libman H, Davis RB, Eisenberg DM. Delays in protease inhibitor use in clinical practice. J Gen Intern Med 1999 14 (7 395 401.
26. Bouhnik AD, Preau M, Vincent E et al. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther 2005 10 (1 53 61.
27. Villes V, Spire B, Lewden C et al. The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice. Antivir Ther 2007 12 (7 1067 1074.
28. Anastos K, Schneider MF, Gange SJ et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr 2005 39 (5 537 544.
29. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003 64 (6 708 714.
30. Raison CL, Borisov AS, Broadwell SD et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005 66 (1 41 48.
31. Gohier B, Goeb JL, Rannou-Dubas K, Fouchard I, Cales P, Garre JB. Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry 2003 4 (3 115 118.
32. Constant A, Castera L, Dantzer R et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 2005 66 (8 1050 1057.
33. Castera L, Constant A, Bernard PH, de Ledinghen V, Couzigou P. Lifestyle changes and beliefs regarding disease severity in patients with chronic hepatitis C. J Viral Hepat 2006 13 (7 482 488.
34. Fleming CA, Christiansen D, Nunes D et al. Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection. Clin Infect Dis 2004 4 : 572 578.
35. Clifford DB, Evans SR, Yang Y, Gulick RM. The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. AIDS 2005 19 (Suppl. 3 S64 S71.
36. Klein MB, Cooper C, Brouillette MJ et al. CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-Hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. Contemp Clin Trials 2008 29 (4 617 630.
37. Starace F, Ammassari A, Trotta MP et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002 31 (Suppl. 3 S136 S139.
38. Himelhoch S, Medoff DR. Efficacy of antidepressant medication among HIV-positive individuals with depression: a systematic review and meta-analysis. AIDS Patient Care STDS. 2005 19 (12 813 822.
39. Mauss S. Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management. J Hepatol 2006 44 (Suppl. 1 S114 S118.
40. Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. J Acquir Immune Defic Syndr 2006 42 (3 298 306.
41. Henry C, Demotes-Mainard J. Avoiding drug-induced switching in patients with bipolar depression. Drug Saf 2003 26 (5 337 351.
42. Cook JA, Grey D, Burke-Miller J et al. Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi-site cohort of HIV-positive women. AIDS Care 2006 18 (2 93 100.
43. Fumaz CR, Munoz-Moreno JA, Ballesteros AL et al. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients. AIDS Care 2007 19 (1 138 145.
44. Duran S, Spire B, Raffi F et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001 2 (1 38 45.
45. Protopopescu C, Marcellin F, Spire B et al. Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8). Qual Life Res 2007 16 (4 577 591.
46. Ammassari A, Murri R, Pezzotti P et al. Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection. J Acquir Immune Defic Syndr 2001 28 (5 445 449.
47. Carrieri MP, Villes V, Raffi F et al. Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8). Int J Drug Policy 2007 18 (4 288 295.
48. Carrico AW, Johnson MO, Morin SF et al. Correlates of suicidal ideation among HIV-positive persons. AIDS 2007 21 (9 1199 1203.
49. Zehnter E. Treatment of Chronic Hepatitis C With Peginterferon alfa-2a (PEG) and Ribavirin (RBV) in Patients With HIV Coinfection in the Real-Life Setting in Germany. Boston : AASLD meeting, 2007 37 (1 95 100.
50. Shaiova L. The management of opioid-related sedation. Curr Pain Headache Rep 2005 9 (4 239 242.
51. Benyamin R, Trescot AM, Datta S et al. Opioid complications and side effects. Pain Physician 2008 11 (Suppl. 2 S105 S120.
52. Ridge G, Gossop M, Lintzeris N, Witton J, Strang J. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. J Subst Abuse Treat 2008 37 (1 95 100.
53. Daniell HW. DHEAS deficiency during consumption of sustained-action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production. J Pain 2006 7 (12 901 907.
54. Dimsdale JE, Norman D, DeJardin D, Wallace MS. The effect of opioids on sleep architecture. J Clin Sleep Med 2007 3 (1 33 36.
55. Wang D, Teichtahl H, Goodman C, Drummer O, Grunstein RR, Kronborg I. Subjective daytime sleepiness and daytime function in patients on stable methadone maintenance treatment: possible mechanisms. J Clin Sleep Med 2008 6 : 557 562.
56. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 2006 5 : 563 572.
57. Gupta SK, Sellers E, Somoza E, Angles L, Kolz K, Cutler DL. The effect of multiple doses of peginterferon alfa-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. J Clin Pharmacol 2007 47 (5 604 612.
58. Sullivan PS, Dworkin MS. Prevalence and correlates of fatigue among persons with HIV infection. J Pain Symptom Manage 2003 25 (4 329 333.
59. Bonkovsky HL, Snow KK, Malet PF et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2007 46 (3 420 431.
60. Rihs TA, Begley K, Smith DE et al. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med 2006 7 (8 544 548.
61. Ward DJ, Curtin JM. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS. 2006 20 (8 542 548.
62. Spire B, Carrieri P, Garzot MA, L'Henaff M, Obadia Y. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care 2004 16 (5 558 564.
63. Golub ET, Latka M, Hagan H et al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the beck depression inventory. J Urban Health 2004 81 (2 278 290.